The AETC Capitol Region Telehealth "Power Podcast" series allows you to listen to experts in the field from your computer or mobile device. Designed for the busy professional, you can learn about cultural competence in the treatment of HIV/AIDS from your office or "On-The-Go."
HIV/AIDS and Chronic Hepatitis Co-Infection: Part III
- Describe the epidemiology -- including trends and at-risk groups -- and natural history of infections due to human immunodeficiency virus (HIV) and hepatitis C virus (HCV), respectively, in the United States.
- Outline the current Centers for Disease Control and Prevention (CDC) guidelines for screening for -- and diagnosing -- HIV and HCV infections.
- State general principles -- including those concerning recommended initial and follow-up laboratory evaluation and initial and salvage treatment regimens -- for caring for persons infected with HIV or HCV, emphasizing principles of the care of persons co-infected with both of these viruses.
- Describe emerging treatment options for persons co-infected with both HIV and HCV and how these emerging treatment modalities are expected to enhance patients' acceptance of antiviral treatment and their long-term prognosis.
Click here to view the slides (Slides coming soon!)
Case Study: Treating HCV Infection in HCV/HIV Coinfected Patients
Mr. JW, a 34-year-old African-American man who has sex with men (MSM), was diagnosed with HIV infection in July 2013 after being found to have a positive rapid oral-fluid HIV test at a club as part of a HIV-testing outreach project conducted by a community-based AIDS service organization.
A baseline HIV genotyping assay showed wild-type HIV-1 with no mutations conferring resistance to nucleoside reverse transcriptase (RT) inhibitors (NRTIs), non-nucleoside RT inhibitors (NNRTIs), protease inhibitors (PIs), or integrase inhibitors (InIs).
He began antiretroviral therapy (ART) with daily efavirenz/emtrictabine/tenofovir (Atripla) in August 2013 and has consistently had non-detectable plasma HIV-1 viral loads (<50 copies/mL) since October 2013. CD4 count was 507 cells/mm3 in January 2014.
HCV antibody testing was negative in 2010 but positive in August 2013.
About the Speaker
H. Gene Stringer, Jr., M.D., is Associate Professor of Clinical Medicine and, since 1998, Chief of the Infectious Diseases Section in the Department of Medicine at Morehouse School of Medicine in Atlanta, Georgia, where, between 2008 and 2010, he served as co-principal investigator of the Morehouse School of Medicine regional performance site within the National Minority AIDS Education and Training Center (NMAETC) network.
He is Co-Medical Director of the 400-client Joye Bradley Health Services Clinic at AID Atlanta, Inc., the largest and most comprehensive AIDS service organization in the southeastern United States, and has served since 1992 as an attending physician at Grady Memorial Hospital.